10/20/21, 11:18 AM
`
`Neue Therapieoptionen in der Behandlung der pulmonalarteriellen Hypertonie | SpringerLink
`
`Search
`
`Log in
`
`Published: June 2005
`Neue Therapieoptionen
`in der Behandlung der
`pulmonalarteriellen
`Hypertonie
`
`Emerging Therapies for the Treatment of Pulmonary
`Arterial Hypertension
`
`,
`
`Hossein Ardeschir Ghofrani
`Robert Voswinckel,
`Frank Reichenberger,
`Friedrich Grimminger &
`Werner Seeger
`
`Herz Kardiovaskuläre Erkrankungen 30, 296–302
`(2005)
`
`89 Accesses
`
`2 Citations
`
`3 Altmetric
`
`Metrics
`
`Zusammenfassung
`
`https://link.springer.com/article/10.1007/s00059-005-2695-4
`
`1/6
`
`IPR2021-00406
`United Therapeutics EX2037
`Page 1 of 6
`
`
`
`Neue Therapieoptionen in der Behandlung der pulmonalarteriellen Hypertonie | SpringerLink
`
`Search
`
`Log in
`
`Published: June 2005
`Neue Therapieoptionen
`in der Behandlung der
`pulmonalarteriellen
`Hypertonie
`
`Emerging Therapies for the Treatment of Pulmonary
`Arterial Hypertension
`
`,
`
`Hossein Ardeschir Ghofrani
`Robert Voswinckel,
`Frank Reichenberger,
`Friedrich Grimminger &
`Werner Seeger
`
`Herz Kardiovaskuläre Erkrankungen 30, 296–302
`(2005)
`
`89 Accesses
`
`2 Citations
`
`3 Altmetric
`
`Metrics
`
`Zusammenfassung
`
`https://link.springer.com/article/10.1007/s00059-005-2695-4
`
`1/6
`
`IPR2021-00406
`United Therapeutics EX2037
`Page 1 of 6
`
`
`
`10/20/21, 11:18 AM
`Neue Therapieoptionen in der Behandlung der pulmonalarteriellen Hypertonie | SpringerLink
`Trotz aller Fortschritte in der Therapie der
`pulmonalarteriellen Hypertonie gibt es bisher keine
`Aussicht auf Heilung dieser schwerwiegenden
`Erkrankung. Mit der Einführung effektiver und
`nonparenteraler Medikamente (z. B. orale
`Endothelin-Rezeptor-Antagonisten [ERA], inhalative
`Prostanoide) haben sich jedoch die Lebensqualität,
`die körperliche Belastbarkeit und die Prognose der
`Patienten in den letzten Jahren erheblich verbessern
`lassen. Die Anwendbarkeit dieser Medikamente ist
`aber durch die z. T. gravierenden Nebenwirkungen
`und/oder aufwendigen Applikationsformen
`eingeschränkt. Ob selektive ERA aufgrund ihrer
`Spezifität für den A-Rezeptor Vorteile gegenüber dem
`nichtselektiven ERA Bosentan im Hinblick auf
`Nebenwirkungen, aber auch in Bezug auf die
`Effektivität haben, wird erst nach Auswertung der
`derzeit laufenden zulassungsrelevanten Studien mit
`Ambrisentan und Sitaxsentan zu eruieren sein.
`Inhaliertes Treprostinil könnte aufgrund seiner
`hohen Selektivität für die pulmonale Zirkulation
`sowie aufgrund der längeren Wirkung einen Vorteil
`gegenüber dem bereits zugelassenen inhalierten
`Iloprost haben. Bisher stehen jedoch noch Ergebnisse
`einer kontrollierten randomisierten Studie aus, die
`die Wirksamkeit dieser Therapie in der chronischen
`Anwendung dokumentieren. Der selektive
`Phosphodiesterase-5-(PDE5-)Inhibitor Sildenafil ist
`im Vergleich zu den vorgenannten Substanzen
`bereits am nächsten zur klinischen Zulassung.
`Sildenafil erwies sich bei verschiedenen Formen der
`pulmonalen Hypertonie als starker pulmonal
`selektiver Vasodilatator. Die Ergebnisse der Phase-
`
`https://link.springer.com/article/10.1007/s00059-005-2695-4
`
`2/6
`
`Page 2 of 6
`
`
`
`10/20/21, 11:18 AM
`Neue Therapieoptionen in der Behandlung der pulmonalarteriellen Hypertonie | SpringerLink
`III-Studie zur Anwendung von Sildenafil bei
`pulmonalarterieller Hypertonie bestätigen die
`hervorragende Wirksamkeit dieses Medikaments bei
`exzellenter Verträglichkeit. Kombinationstherapien
`stellen bei allen noch zu erwartenden Fortschritten in
`der Entwicklung einzelner Substanzen die
`aussichtsreichste zukünftige Therapieoption dar.
`Kontrollierte Studien zur Überprüfung dieser Option,
`unter Berücksichtigung verschiedener
`Medikamentenkombinationen, befinden sich bereits
`in Planung.
`
`Abstract
`
`Besides all progress in the therapy of pulmonary
`arterial hypertension over the past years, there is still
`no cure for this devastating disease. By introducing
`effective and nonparenteral medications (e. g., oral
`endothelin receptor antagonists [ERAs], inhaled
`prostanoids), quality of life, exercise tolerance and
`prognosis of patients have substantially improved.
`However, applicability of these therapies can be
`hampered by serious side effects and/or the necessity
`for elaborate application techniques. Whether
`selective ERAs—due to their specificity for the A-type
`receptor—have potential benefits over the
`nonselective ERA bosentan remains to be answered
`by the analysis of pivotal trials recently carried out
`with ambrisentan and sitaxsentan. Inhaled
`treprostinil can potentially have benefits over the
`already approved inhaled iloprost, related to its
`higher pulmonary selectivity as well as to the longer
`biological half-life. However, this has yet to be proven
`
`https://link.springer.com/article/10.1007/s00059-005-2695-4
`
`3/6
`
`Page 3 of 6
`
`
`
`10/20/21, 11:18 AM
`Neue Therapieoptionen in der Behandlung der pulmonalarteriellen Hypertonie | SpringerLink
`in long-term randomized controlled trials. In
`comparison to the previously mentioned substances,
`the selective phosphodiesterase-5 (PDE5) inhibitor
`sildenafil approached approval closest as new
`therapy for pulmonary arterial hypertension. Oral
`sildenafil has proven its efficacy as a selective
`pulmonary vasodilator in various forms of pulmonary
`hypertension. The results of the pivotal phase III trial
`have confirmed the strong efficacy and excellent
`tolerability of this substance. Combination therapies,
`despite all progress seen for single agents, can be
`regarded as the most promising therapeutic approach
`for the future. However, controlled randomized trials
`that are currently under consideration have to
`confirm this notion.
`
`This is a preview of subscription content, access via
`your institution.
`
`Access options
`
`Buy article PDF
`US$ 39.95
`Tax calculation will be finalised during checkout.
`
`Instant access to the full article PDF.
`
`Rent this article via DeepDyve.
`
`Learn more about Institutional subscriptions
`
`https://link.springer.com/article/10.1007/s00059-005-2695-4
`
`4/6
`
`Page 4 of 6
`
`
`
`10/20/21, 11:18 AM
`
`Neue Therapieoptionen in der Behandlung der pulmonalarteriellen Hypertonie | SpringerLink
`
`Author information
`
`Affiliations
`
`1. Medizinische Klinik und Poliklinik II, University
`Giessen Lung Center UGLC), Justus-Liebig-
`Universität, Gießen
`
`Werner Seeger
`
`2. Medizinische Klinik II, Klinikstraße 36, 35392,
`Gießen
`
`Hossein Ardeschir Ghofrani
`
`Corresponding author
`Correspondence to Hossein Ardeschir Ghofrani.
`
`Rights and permissions
`
`Reprints and Permissions
`
`About this article
`
`Cite this article
`Ghofrani, H.A., Voswinckel, R., Reichenberger, F. et
`al. Neue Therapieoptionen in der Behandlung der
`pulmonalarteriellen Hypertonie. Herz 30, 296–302
`(2005). https://doi.org/10.1007/s00059-005-2695-4
`
`Issue DateJune 2005
`
`https://link.springer.com/article/10.1007/s00059-005-2695-4
`
`5/6
`
`Page 5 of 6
`
`
`
`10/20/21, 11:18 AM
`Neue Therapieoptionen in der Behandlung der pulmonalarteriellen Hypertonie | SpringerLink
`DOIhttps://doi.org/10.1007/s00059-005-2695-
`4
`
`Schlüsselwörter:
`Pulmonale Hypertonie
`Vasodilatative Therapie
`Stickstoffmonoxid
`Prostacyclin
`Endothelinantagonist
`Phosphodiesteraseinhibitoren
`Kombinationstherapien
`Key Words:
`Pulmonary hypertension
`Vasodilative therapy
`Nitric oxide
`Prostacyclin
`Endothelin antagonist
`Phosphodiesterase inhibitors
`Combination therapies
`
`Not logged in - 38.142.127.10
`
`Not affiliated
`
`© 2021 Springer Nature Switzerland AG. Part of Springer Nature.
`
`https://link.springer.com/article/10.1007/s00059-005-2695-4
`
`6/6
`
`Page 6 of 6
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
